Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
InChI
InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00927Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Sources: http://www.drugbank.ca/drugs/DB00927
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8204567
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: http://www.drugbank.ca/drugs/DB00927 |
0.3 µM [IC50] | ||
Target ID: CHEMBL2073673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16141367 |
6.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
|||
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
|||
Primary | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date5.29632002E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
424 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 mg/kg 2 times / day steady, oral Recommended Dose: 0.5 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.5 mg/kg, 2 times / day Sources: |
unhealthy, 11 - 15 years n = 8 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 11 - 15 years Sex: M Population Size: 8 Sources: |
|
80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Other AEs: Dizziness, Dry skin... Other AEs: Dizziness (grade 1, 2 patients) Sources: Dry skin (grade 1, 1 patient) Insomnia (grade 1, 1 patient) Gastrointestinal disorder (NOS) (grade 1, 1 patient) Forgetfulness (grade 1, 1 patient) |
1 mg/kg 1 times / day steady, intravenous Recommended Dose: 1 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 1 mg/kg, 1 times / day Sources: |
unhealthy, 6 - 15 years n = 6 Health Status: unhealthy Condition: gastric or duodenal ulcers Age Group: 6 - 15 years Sex: M Population Size: 6 Sources: |
|
26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Other AEs: Anemia, Nausea... Other AEs: Anemia (2 patients) Sources: Nausea (6 patients) Dyspepsia (5 patients) Diarrhea (5 patients) Constipation (4 patients) Abdominal pain upper (3 patients) Gastroesophageal reflux disease (2 patients) Vomiting (2 patients) Stomach discomfort (2 patients) Abdominal pain (2 patients) Edema peripheral (2 patients) Arthralgia (1 patient) Back pain (2 patients) Headache (3 patients) Hypertension (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry skin | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Forgetfulness | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Gastrointestinal disorder (NOS) | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Insomnia | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Dizziness | grade 1, 2 patients | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years n = 10 Health Status: unhealthy Condition: COVID-19 Age Group: 20 - 70 years Sex: M+F Population Size: 10 Sources: |
Arthralgia | 1 patient | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Anemia | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Back pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Edema peripheral | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Gastroesophageal reflux disease | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Stomach discomfort | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Vomiting | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Abdominal pain upper | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Headache | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Hypertension | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Constipation | 4 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Diarrhea | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Dyspepsia | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Nausea | 6 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Co-administed with:: ibuprofen(800 mg) Sources: |
unhealthy, adult n = 1022 Health Status: unhealthy Condition: chronic pain and inflammation of stomach Age Group: adult Sex: M+F Population Size: 1022 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
weak | likely (co-administration study) Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value Page: 6.0 |
||
yes [IC50 114 uM] | ||||
yes [IC50 28 uM] | ||||
yes [IC50 6.7 uM] | ||||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
yes [Ki 0.6 uM] | ||||
yes [Ki 9.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. | 1992 Mar |
|
Histamine regulation of interleukin-18-initiating cytokine cascade is associated with down-regulation of intercellular adhesion molecule-1 expression in human peripheral blood mononuclear cells. | 2002 Jan |
|
H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. | 2002 Jul |
|
Omeprazole-induced acute interstitial nephritis. | 2003 Feb 21 |
|
[A successfully treated case of intraoperative latex anaphylaxis during abdominal aorta aneurysm resection]. | 2003 Jan |
|
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). | 2004 Oct 25 |
|
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. | 2004 Sep |
|
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. | 2005 Apr |
|
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. | 2005 Dec |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. | 2005 Jun |
|
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. | 2005 Jun |
|
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. | 2005 Jun |
|
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. | 2006 Mar |
|
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection. | 2006 Oct 20 |
|
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors. | 2007 Oct |
|
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. | 2008 Winter |
|
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. | 2009 |
|
Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor. | 2009 |
|
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. | 2009 Apr |
|
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. | 2009 Dec |
|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. | 2010 Apr |
|
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. | 2010 Apr |
Patents
Sample Use Guides
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23857299
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:28:48 UTC 2022
by
admin
on
Fri Dec 16 18:28:48 UTC 2022
|
Record UNII |
5QZO15J2Z8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA03
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
||
|
NDF-RT |
N0000175784
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
||
|
WHO-VATC |
QA02BA03
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
||
|
WHO-ATC |
A02BA53
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
||
|
LIVERTOX |
NBK548228
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
||
|
WHO-VATC |
QA02BA53
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
||
|
NDF-RT |
N0000000151
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Famotidine
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
DTXSID5023039
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
DB00927
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
757810
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
D015738
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
SUB07503MIG
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
5217
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
7074
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
3325
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
M5241
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | Merck Index | ||
|
CHEMBL902
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
4278
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | RxNorm | ||
|
FAMOTIDINE
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
1269200
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
4975
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
1129
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
W-33
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
3572
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
C29045
Created by
admin on Fri Dec 16 18:28:49 UTC 2022 , Edited by admin on Fri Dec 16 18:28:49 UTC 2022
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY | |||
|
76824-35-6
Created by
admin on Fri Dec 16 18:28:48 UTC 2022 , Edited by admin on Fri Dec 16 18:28:48 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
Following IV administration
URINE
|
||
|
TARGET->INVERSE AGONIST |
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->INVERSE AGONIST |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> NON-INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||